Parnax Lab
Ticker >

Parnax Lab share price

Parnax Lab Ltd.

BSE: 506128 SECTOR: Pharmaceuticals & Drugs  9319   12   3

129.00
+1.85 (1.45%)
BSE: 24 Apr 04:01 PM

Price Summary

Today's High

₹ 131.85

Today's Low

₹ 127

52 Week High

₹ 167.9

52 Week Low

₹ 55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 148.16 Cr.

Enterprise Value

₹ 147.95 Cr.

No. of Shares

1.15 Cr.

P/E

62.36

P/B

7.05

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  18.29

CASH

₹ 1.28 Cr.

DEBT

₹ 1.07 Cr.

Promoter Holding

72.3 %

EPS (TTM)

₹  2.07

Sales Growth

4.53%

ROE

7.95 %

ROCE

8.85%

Profit Growth

122.46 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year4.53%
3 Year-0.9%
5 Year5.19%

Profit Growth

1 Year122.46%
3 Year37.52%
5 Year20.13%

ROE%

1 Year7.95%
3 Year-2.2%
5 Year-9.21%

ROCE %

1 Year8.85%
3 Year4.7%
5 Year4.4%

Debt/Equity

0.0554

Price to Cash Flow

-526

Interest Cover Ratio

7.53411998120399

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 72.3 9.41
Dec 2023 72.3 9.41
Sep 2023 72.3 9.41
Jun 2023 72.3 9.41
Mar 2023 72.3 9.41
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 8.124469 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.692117639113096.
  • The company has an efficient Cash Conversion Cycle of 22.3425554608831 days.
  • Company has a healthy liquidity position with current ratio of 3.52718469956868.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.38943724559876.

 Limitations

  • The company has shown a poor revenue growth of -0.901117616155089% for the Past 3 years.
  • Company has a poor ROE of -2.20499316132539% over the past 3 years.
  • Company has a poor ROCE of 4.69662630304701% over the past 3 years
  • Company has negative cash flow from operations of -0.281679.
  • The company is trading at a high PE of 62.36.
  • The company is trading at a high EV/EBITDA of 43.1217.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 1.16 2.44 1.13 1.83 2.77
Total Expenditure 1.04 1.52 1.11 1.13 1.54
Operating Profit 0.12 0.92 0.02 0.7 1.23
Other Income 0.13 0.14 0.12 0.18 0.13
Interest 0.06 0.03 0.04 0.07 0.02
Depreciation 0.01 0.03 0.01 0.02 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.18 0.99 0.09 0.79 1.33
Tax 0.07 0.27 0.02 0.19 0.34
Profit After Tax 0.11 0.73 0.07 0.6 0.99
Adjusted EPS (Rs) 0.09 0.63 0.06 0.52 0.86

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 6.49 7.68 2.37 7.15 7.47
Total Expenditure 6.39 7.14 2.83 5.78 5.9
Operating Profit 0.11 0.53 -0.46 1.37 1.57
Other Income 0.51 0.42 0.08 0.16 0.37
Interest 1.08 1.38 0.83 0.71 0.25
Depreciation 0.05 0.04 0.04 0.04 0.07
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.51 -0.47 -1.25 0.78 1.63
Tax 0.32 1.53 -0.12 0.24 0.42
Net Profit -0.83 -2 -1.13 0.54 1.2
Adjusted EPS (Rs.) -0.97 -2.36 -1.33 0.55 1.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 8.5 8.5 8.5 9.81 11.49
Total Reserves -0.68 -2.68 -3.79 2.93 7.87
Borrowings 8.33 2.77 1.89 1.15 0.16
Other N/C liabilities -2.58 -1.05 -1.3 -1.07 -0.66
Current liabilities 4.24 10.04 11.03 9.63 1.84
Total Liabilities 17.81 17.59 16.33 22.46 20.7
Assets
Net Block 0.57 0.53 0.49 0.44 0.43
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 10.07 10.07 10.07 10.07 10.03
Loans & Advances 0.05 0.05 0.05 0 0
Other N/C Assets 0 3.74 3.78 3.79 3.74
Current Assets 7.12 3.2 1.95 8.16 6.5
Total Assets 17.81 17.59 16.33 22.46 20.7
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -0.51 -0.47 -1.25 0.78 1.63
Adjustment 1.19 1.42 0.86 0.82 0.18
Changes in Assets & Liabilities 0.93 1.23 0.87 -1.96 -2.07
Tax Paid 0.07 0.02 0 0 -0.01
Operating Cash Flow 1.68 2.2 0.47 -0.36 -0.28
Investing Cash Flow 0.03 -0.01 0 0 0.14
Financing Cash Flow -2.25 -1.55 -0.48 4.59 -2.92
Net Cash Flow -0.55 0.64 -0.01 4.23 -3.07

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 72.30 72.30 72.30 72.30 72.30
ami mihir shah 7.26 7.26 7.26 7.26 7.26
baiju mahasukhlal shah 11.57 11.57 11.57 11.57 11.57
binoy baiju shah 11.92 11.92 11.92 11.92 11.92
ila b shah 11.86 11.86 11.86 11.86 11.86
mihir prakash shah 9.94 9.94 9.94 9.94 9.94
pragna prakash shah 9.28 9.28 9.28 9.28 9.28
prakash mahasukhlal shah 10.46 10.46 10.46 10.46 10.46
PARTICULARS Dec 2022% Mar 2023% Sep 2023% Dec 2023% Mar 2024%
investors 27.70 27.70 27.70 27.70 27.70
suman gupta 1.57 1.62 1.62 1.62 1.62

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Parnax Lab Stock Price Analysis and Quick Research Report. Is Parnax Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Parnax Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Parnax Lab cash from the operating activity was Rs -0.281679 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Parnax Lab has a Debt to Equity ratio of 0.0554 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Parnax Lab , the EPS growth was 90.1033170201196 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Parnax Lab has OPM of 21.0453049318954 % which is a good sign for profitability.
     
  • ROE: Parnax Lab have a poor ROE of 7.9549008834336 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Parnax Lab is Rs 129. One can use valuation calculators of ticker to know if Parnax Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Parnax Lab
X